30
Participants
Start Date
October 1, 2018
Primary Completion Date
February 1, 2019
Study Completion Date
May 1, 2019
Liraglutide
Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM.
placebo
Any hypoglycemic drugs except glucagon-like peptide type 1 (GLP-1) analogue.
The third hospital affiliated to the Third Military Medical University, Chongqing
Third Military Medical University
OTHER